Feedback    Advertise    Submit Papers    Reprints    About    Help    Contact   
Upstream Processing Downstream Processing Manufacturing Analytical Facilities
Archive by Issue Archive by Article Type Supplements
CMC Forum Press Releases
Rare Disease Organizations Form Strategic Alliance
BioProcess International, Vol. 7, No. 11, December 2009, pp. 8–9
 

Two major advocacy groups for people with rare diseases — the National Organization for Rare Disorders (NORD, www.rarediseases.org) in the United States and the European Organization for Rare Diseases (EURORDIS, www.eurordis.org) — have joined forces to work on behalf of rare disease patients and their families in both regions. These groups are nongovernmental (NGO), patient-driven alliances of patient organizations and individuals dedicated to improving the lives of people with rare diseases.

This collaboration follows an announcement by the US FDA and the EMEA of a collaborative effort to ensure appropriate conduct of clinical trials and adoption of a common application for orphan drug products — those being developed to treat rare diseases. The intent is to increase global awareness, promote research and the development of new treatments, and provide advocacy for more compassionate public policies, according to press releases from the NGOs.

A disease is considered rare in the United States if it affects <200,000 Americans. Almost 30 million (nearly one in 10) Americans have a rare disease. In the European Union, a disease is considered rare if it affects fewer than one in 2,000 people. There are 30 million Europeans with rare diseases.

 
| | Share
Biopharmaceutical Production
Facility Design Strategies for Single-Use Technologies

Please join us for a free webinar addressing strategies for facility design in biopharmaceutical manufacturing:

Wednesday, 29 February 2012
8:00 AM and 1:00 PM EST

Presented by:

Ingrid Long, MSc
Research Engineer
GE Healthcare Life Sciences

Register today!

During the webinar, Ms. Long will discuss the impact of different strategies for facility design, with a focus on the following topics:

* Replacement of traditional equipment with the single-use equivalent
* Biopharmaceutical manufacturing in a single room
* Benefits of facility design with respect to cost, risk, and flexibility

Register today!


Nine Conferences — One Location: Hilton Bayfront (San Diego, CA)
Webinars   
Subscribe   
Reprints   
Contact   
About   
Informa plc
©2002 - 2009 BioProcess International
Ph: 508-616-5550